Kinfo
Connect Biopharma Holdings Limited logo

Connect Biopharma Holdings Limited

CNTBNASDAQHealthcare·US · USD
$2.46
+0.08 (+3.36%)
Live · 2026-06-30

Price

Key statistics

Valuation
Market cap137.89M USD
Enterprise value92.55M USD
Trailing P/E-2.39
Forward P/E-2.20
PEG ratio-0.03
Price / sales591.81
Price / book3.22
Profitability
Gross margin0.00%
Operating margin-11601.78%
Profit margin0.00%
Return on assets-54.20%
Return on equity-102.94%
Income (TTM)
Revenue233.00K USD
Gross profit233.00K USD
EBITDA-65.54M USD
Net income-64.61M USD
Diluted EPS-$1.15
Rev. growth (YoY)0.00%
Balance sheet
Total cash46.03M USD
Total debt693.00K USD
Debt / equity1.63
Current ratio3.23
Book value / share$0.68
Cash flow (TTM)
Operating cash flow-57.25M USD
Levered free cash flow-33.88M USD
Shares & price
Shares outstanding62.71M
Float18.86M
Held by institutions54.26%
Beta0.00
50-day MA$2.34
200-day MA$2.33
52-week high$3.82
52-week low$0.98
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-03-31-0.30-0.27+10.00%2026-02-063.186.15+93.40%2025-11-282.942.57−12.59%2025-11-12-0.23-0.31−34.78%2025-08-13-0.22-0.23−4.55%
About Connect Biopharma Holdings Limited

Connect Biopharma Holdings Ltd. is a global clinical-stage biopharmaceutical company focused on developing innovative therapies for T cell-driven inflammatory diseases. Headquartered in San Diego, California with operations in the United States and China, the company builds a pipeline of proprietary small molecules and antibodies using functional T cell assays to identify and validate therapeutic targets. Its lead product candidate, rademikibart, is an antibody targeting interleukin-4 receptor alpha currently in Phase 3 clinical development for atopic dermatitis and asthma. The company's second product candidate, icanbelimod, is an oral small molecule modulator of Sphingosine 1-Phosphate Receptor 1 in Phase 2 development for ulcerative colitis and Crohn's disease. Connect Biopharma aims to improve treatment outcomes for patients with chronic inflammatory conditions by leveraging advanced immunological research and targeted drug development strategies.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Barry D. Quart Pharm.D.
Employees
64
Headquarters
San Diego, CA, United States

Frequently asked questions about Connect Biopharma Holdings Limited